Molecular Pharmacology Valuation
| MLPH Stock | USD 0.0001 0.00 0.00% |
Molecular Pharmacology seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of Molecular Pharmacology from analyzing the firm fundamentals such as EBITDA of (98.11 K), return on asset of -5.69, and Shares Outstanding of 111.55 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Molecular Pharmacology's price fluctuation is out of control at this time. Calculation of the real value of Molecular Pharmacology is based on 3 months time horizon. Increasing Molecular Pharmacology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Molecular Pharmacology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Molecular Pink Sheet. However, Molecular Pharmacology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 9.6E-5 | Hype 1.04E-4 |
The intrinsic value of Molecular Pharmacology's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Molecular Pharmacology's stock price.
Estimating the potential upside or downside of Molecular Pharmacology helps investors to forecast how Molecular pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Molecular Pharmacology more accurately as focusing exclusively on Molecular Pharmacology's fundamentals will not take into account other important factors: Molecular Pharmacology Total Value Analysis
Molecular Pharmacology is now projected to have valuation of 221.59 K with market capitalization of 26.77 K, debt of 175.33 K, and cash on hands of 1.52 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Molecular Pharmacology fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
221.59 K | 26.77 K | 175.33 K | 1.52 K |
Molecular Pharmacology Asset Utilization
One of the ways to look at asset utilization of Molecular is to check how much profit was generated for every dollar of assets it reports. Molecular Pharmacology secures a negative usage of assets of -5.69 %, losing $0.0569 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Molecular Pharmacology shows how discouraging it operates for each dollar spent on its assets.Molecular Pharmacology Profitability Analysis
Net Loss for the year was (116.93 K) with profit before overhead, payroll, taxes, and interest of 0.About Molecular Pharmacology Valuation
An absolute valuation paradigm, as applied to Molecular Pink Sheet, attempts to find the value of Molecular Pharmacology based on its fundamental and basic technical indicators. By analyzing Molecular Pharmacology's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Molecular Pharmacology's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Molecular Pharmacology. We calculate exposure to Molecular Pharmacology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Molecular Pharmacology's related companies.Molecular Pharmacology Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. Molecular Pharmacology Limited is a subsidiary of PharmaNet Group Limited. Molecular Pharmacology is traded on OTC Exchange in the United States.
8 Steps to conduct Molecular Pharmacology's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Molecular Pharmacology's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Molecular Pharmacology's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Molecular Pharmacology's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Molecular Pharmacology's revenue streams: Identify Molecular Pharmacology's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Molecular Pharmacology's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Molecular Pharmacology's growth potential: Evaluate Molecular Pharmacology's management, business model, and growth potential.
- Determine Molecular Pharmacology's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Molecular Pharmacology's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Molecular Pink Sheet analysis
When running Molecular Pharmacology's price analysis, check to measure Molecular Pharmacology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Pharmacology is operating at the current time. Most of Molecular Pharmacology's value examination focuses on studying past and present price action to predict the probability of Molecular Pharmacology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Pharmacology's price. Additionally, you may evaluate how the addition of Molecular Pharmacology to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |